vimarsana.com
Home
Live Updates
LumiraDx Limited: LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test : vimarsana.com
LumiraDx Limited: LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test
- Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral
Related Keywords
United States
,
United Kingdom
,
London
,
City Of
,
Ron Zwanziger
,
Colleen Mcmillen
,
Exchange Commission
,
Department Of Health
,
Human Services
,
National Institutes Of Health
,
Drug Administration
,
National Institute Of Biomedical Imaging
,
Lumiradx Platform
,
Emergency Use Authorization
,
Lumiradx Point
,
Care Platform
,
Lumiradx Chief Executive Officer
,
National Institute
,
Biomedical Imaging
,
National Institutes
,
Securities Litigation Reform Act
,
Proxy Statement
,
Lumiradx
,
Imited
,
Nnounces
,
Submission
,
Cars
,
Rapid
,
Ntigen
,
Pest
,
vimarsana.com © 2020. All Rights Reserved.